KLK3 and cancer: A biomarker that could replace or complement PSA with improved positive (PPV) and negative (NPV) predictive values to rule in intermediate- to high-grade cancers (ISUP 2–5) [4] but rule out benign lesions as well as low-grade cancers is warranted and would consequently decrease the number of men needing MRI.